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Abstract
Background: Nonadherence to prescribed medication regimens is a substantial barrier to the pharmacological
management of alcohol use disorders. The availability of low-cost, sustainable interventions that maximize
medication adherence would likely lead to improved treatment outcomes. Mobile health (mHealth) technologies
are increasingly being adopted as a method of delivering behavioral health interventions and represent a
promising tool for adherence interventions. We are evaluating a cell-phone–based intervention called AGATE that
seeks to enhance adherence with regular text-messaging.
Methods/Design: A randomized controlled effectiveness trial in the context of an eight-week open label
naltrexone efficacy trial delivered in a naturalistic clinical setting. Treatment-seeking heavy drinkers (N = 105) are
currently being recruited and randomly assigned to the AGATE intervention or a control condition. Daily measures
of alcohol use and medication side effects are being recorded via cell phone in both conditions. Additionally,
participants randomized to the AGATE condition receive medication reminders via SMS text message according to
a schedule that adjusts according to their level of adherence.
Discussion: Results from this trial will provide initial information about the feasibility and efficacy of mHealth
interventions for improving adherence to alcohol pharmacotherapies.
Trial Registration: NCT01349985.
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Background
Alcohol-related disorders contribute significantly to the
global disease burden, accounting for an estimated 3.8% of
deaths and 4.6% of disability-adjusted life years worldwide
[1]. In the United States, recent estimates of annual eco-
nomic costs attributed to alcohol consumption surpass
$220 billon, equivalent to 2–3% of the gross domestic
product [1,2]. Pharmacotherapy is one efficacious treat-
ment option [3–5]; however, underutilization of pharma-
cotherapy and medication nonadherence remain
significant barriers to its clinical utility [3,6–8]. Alcohol
use itself is a significant risk factor for nonadherence to
medication regimens [9–11], further undermining the po-
tential efficacy of pharmacotherapy for alcohol problems.
Naltrexone is one of three medications approved by the
US Food and Drug Administration for the treatment of al-
cohol dependence. Naltrexone has shown efficacy for re-
ducing levels of alcohol use in those diagnosed with
alcohol dependence [12] and may also facilitate reductions
in heavy drinking in nondependent individuals with high-
risk drinking [13]. Satisfactory adherence to naltrexone is
critical to its efficacy, as demonstrated in several clinical
trials [14–18]. Unfortunately, average rates of adherence
to naltrexone pharmacotherapy are suboptimal, ranging
from 55–85% over short-term periods (e.g., 12–16 weeks)
[14,16–21] with poorer rates observed over lengthier as-
sessment periods [20]. These estimates are based mainly
on clinical trials that often include regular monitoring and
are, therefore, likely to overestimate rates of adherence
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that can be expected in naturalistic settings. Naltrexone
remains relatively underutilized by US physicians, who
cite concerns about nonadherence as the most common
reason for not prescribing this potentially valuable treat-
ment [8]. Thus, identification and remediation of barriers
to naltrexone adherence in naturalistic settings could help
address prescribers’ concerns about nonadherence and im-
prove clinical outcomes.
Ongoing monitoring of medication adherence is likely
critical for maximizing treatment efficacy. A recent sys-
tematic review of randomized placebo-controlled studies
of naltrexone for alcohol problems reported a significant
association between the intensity of adherence assess-
ments and the likelihood of returning to heavy drinking
during treatment [7]. Although structured behavioral
programs are available to help maximize medication ad-
herence during pharmacological management of alcohol
use disorders [22], the implementation of these programs
in naturalistic settings is variable at best. In addition, inter-
ventions to improve adherence to alcohol pharmacothera-
pies often assess adherence on, at most, a weekly basis
[22]. Consequently, there is a need for supplemental inter-
ventions to maximize adherence that are easily implemen-
ted, sustainable, and capable of reaching participants on a
regular (if not daily) basis.
Mobile health (mHealth) technologies are increasingly
being used to deliver behavioral health interventions [23]
with one application being the delivery of mobile interven-
tions for improving medication adherence [24,25]. The
current randomized trial was designed to evaluate the effi-
cacy of an mHealth intervention to improve adherence to
naltrexone among treatment-seeking individuals with alco-
hol dependence or at-risk drinking. This cell-phone–based
intervention consists of an adaptive goal-directed adher-
ence tracking and enhancement (AGATE) system for meas-
uring and enhancing medication adherence.
Methods/Design
Overview of AGATE
The AGATE system was developed at Talaria, Inc. (Seattle,
WA). To summarize, AGATE uses a combination of Short
Message Service (SMS) text messages and internet access
on a cellular handset to conduct medication adherence
assessments and reminders. On many handsets (e.g.,
Windows Mobile, iPhone, Blackberry), SMS messages per-
mit the inclusion of live hyperlinks that can launch web-
based assessments. All major carriers in the US and abroad
make it possible for cellular subscribers to receive SMS
messages via email by providing email addresses for this
purpose. Thus, knowledge of the patient’s cell phone num-
ber and carrier are sufficient to deliver SMS messages con-
taining assessments and medication reminders.
An important feature of AGATE is its adaptive cap-
abilities based on self-reported adherence patterns. The
program was designed so that the patient and provider
agree upon, or the researcher sets, an adherence goal (e.g.,
a minimum of 90% of scheduled doses to be taken over a
certain period of time, such as 14 days). In the first stage,
patients or research participants receive a reminder/as-
sessment message for every scheduled dose. If, at the end
of this period, the patient has achieved the goal, he or she
progresses to Stage 2, in which the reminder/assessment
frequency steps down (e.g., to once every few days) for an-
other period of time, such as 21 days. At the end of this
second period, if the goal is maintained, the patient pro-
gresses to Stage 3, in which the reminder/assessment fre-
quency steps down further (e.g., to once per week).
However, if the goal is not maintained in Stage 2 or 3,
messaging frequency steps back up, and the patient
returns to the preceding stage. In this context, patients are
provided regular feedback on their performance and are
reminded of their goal. Participants can also be asked to
complete daily assessments of drinking behavior, such as
number of standard drinks per day and urge to drink,
using the AGATE system.
Study setting and overview
The purpose of this trial (ClinicalTrials.gov identifier
NCT01349985) is to evaluate whether AGATE effectively
measures and enhances medication adherence in the con-
text of a brief naltrexone trial involving treatment-seeking
heavy drinkers. Currently underway at the Mind Research
Network (Albuquerque, NM), this open-label trial seeks
to enroll up to 105 treatment-seeking heavy drinkers from
the area. Qualifying participants must be interested in ei-
ther reducing or stopping their drinking and deemed to
be appropriate candidates for naltrexone by a physician.
Those enrolled in the study will be prescribed naltrexone
(50 mg once daily) for eight weeks. To simulate a real-
world treatment scenario to the extent possible, partici-
pants will be assessed at an outpatient psychiatric clinic
and will meet with a physician for baseline and follow-up
visits at four and eight weeks after initiating medication.
All procedures were reviewed and approved by the
University of New Mexico Health Sciences Center Human
Research Review Committee (HRRC), which retains pri-
mary oversight, as well as Quorum Review (Seattle, WA).
All participants will receive smart phones during the
study. Participants will be randomly assigned to receive
either AGATE (adherence support) or a Structured
Alcohol and Side Effects Diary (SASED) via smart phone.
The primary outcome will be percent of scheduled doses
taken during the eight week trial as measured by elec-
tronic pill cap monitoring (Medication Event Monitoring
System [MEMS], Aardex Group, Union City, CA). Sec-
ondary outcomes will include other indices of medication
adherence assessed via MEMS as well as those measured
via pharmacist pill counts and self-reported adherence
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using the Timeline Followback (TLFB) method [26]. Ter-
tiary outcomes will be selected indicators of alcohol use
over the eight-week trial.
For the current study, SMS reminders to take medica-
tion will be tailored based on the participant’s level of ad-
herence to that point. At the outset, participants will be
reminded daily to take their medication. Upon achieving
adherence for a period of several days, reminders will be
reduced to once every third day. Participants in the con-
trol SASED condition will not receive any medication
reminders; however, all participants will complete daily
drinking measures (e.g., number of standard drinks per
day, urge to drink) via the smart phone interface. These
assessments will be sent each morning to assess drinking
and craving during the prior day and will be identical
across treatment conditions. Additionally, possible side
effects will be assessed daily using brief assessments deliv-
ered concurrent with the drinking assessments. Finally, we
will collect online metrics of number of messages ignored
versus answered and latency to respond to messages
to gauge the use and uptake of both AGATE and
SASED.
Participants and recruitment
Participants will be men and women aged 21–55 years
who report average weekly consumption over the past 3
months of ≥ 14 standard drinks for women and ≥ 21
standard drinks for men assessed via phone screening
and confirmed using TLFB [26]. Additionally, partici-
pants must a) report at least two heavy drinking days
(defined as 4+ drinks in a day for women and 5+ drinks
in a day for men) in a consecutive 30-day period within
the three months prior to baseline evaluation [12]; b) en-
dorse a desire to reduce or stop drinking alcohol and be
willing to try naltrexone; and c) receive medical clear-
ance by the study physician to take naltrexone based on
blood panels and a medical exam.
Exclusion criteria include clinically significant physical
illness; pregnancy or intent to become pregnant in the
forthcoming 8 weeks; current (30-day) drug use other
than alcohol, nicotine, or cannabis as verified by urine
toxicology screen; any recent (past 90-day) use of opioids
or other medications; lifetime opioid dependence [27];
current psychiatric medication other than antidepressants;
lifetime diagnosis of a DSM-IV Axis I psychotic disorder
[27]; baseline score ≥8 on the Clinical Institute With-
drawal Assessment for Alcohol scale [28] (indicating clin-
ically significant alcohol withdrawal); liver enzyme levels
greater than three times the upper limit of the normal
range; concurrent receipt of another pharmacological or
behavioral alcohol treatment (with the exception of Alco-
holics Anonymous); or current court mandate (or other
requirement) to attend treatment for alcohol problems.
Procedures
Potential participants who meet basic eligibility criteria
during preliminary phone screening will be scheduled
for an in-person screening visit. At the in-person screen-
ing visit, participants will meet with the study coordin-
ator to review the details of the study and provide
informed consent. They will then complete the Struc-
tured Clinical Interview for DSM-IV-TR Axis I Disor-
ders (SCID) [27] and a TLFB assessment of drinking
behavior over the preceding 30 days [26] to confirm
presence of inclusion criteria and absence of exclusion
criteria. Alcohol dependence will be assessed using the
SCID but is not a requirement for inclusion. Those
meeting eligibility criteria will provide blood samples for
hepatic tests and a urine sample for a toxicology screen.
Additionally, female participants will complete a urine-
based pregnancy screen. Pending no contraindications
based on blood or urine screen results (which will be
available within 2–3 days after the screening visit), parti-
cipants will be scheduled for their baseline (Week 0) ap-
pointment. At that time, participants will be asked to
remain abstinent from alcohol for 72 hours prior to their
appointment to permit an assessment of potential with-
drawal. At the baseline visit, participants will meet with
the study physician and study coordinator to further de-
termine whether naltrexone is medically appropriate
based on additional medical and psychiatric criteria and
to be assessed for withdrawal symptoms.
If no other medical or psychiatric contraindications
are noted, the participant’s naltrexone prescription will
be forwarded to the pharmacy, and he or she will
proceed with the baseline session by completing a bat-
tery of study questionnaires administered by computer.
Following completion of these questionnaires, the par-
ticipant will meet with the study coordinator for detailed
instructions on using the cell phone and responding to
prompts delivered by the cell phone. At this point, the
participant’s ID number will be entered into the web-
based AGATE/SASED administrative interface, where
computerized randomization will occur. This system is
maintained by Talaria, Inc., but accessible to the study’s
research assistant via web interface using a secure pass-
word. Participants will then be asked to select a drinking
goal of either abstinence or moderation (the latter to be
defined by the participant). The computer randomization
algorithm will block participants according to drinking
goal (abstinence or moderation), ensuring even distribu-
tion of these variables between conditions.
The study coordinator will provide each participant with
a smart phone (SamsungW Prevail) and instruct the par-
ticipant in its use. This overview will include basic func-
tions of the phone, how to respond to SMS prompts, and
guidelines for acceptable use of the phone during the
study. Finally, the participant will pick up his or her four-
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week prescription for naltrexone from the on-site phar-
macy. The pharmacist will fit the pill containers with the
MEMS monitoring system, which will record an electronic
timestamp each time the container is opened (these data
are stored in a microchip in the MEMS cap).
Following the baseline visit, the course of the medica-
tion trial will be eight weeks. During this time, partici-
pants will return for follow-up medical visits at weeks
four and eight, consistent with recommended clinical
guidelines for monitoring patients receiving naltrexone
[19]. At the visit, participants will meet with the study
physician and provide a blood sample. They will also
bring their medication bottles for pill counts and
uploading of MEMS cap data, and will report whether
they have had any problems with their phone or the
AGATE system. Participants will then complete a brief
subset of the study questionnaires (e.g., assessment of
drinking and medication adherence in the last four
weeks). If any medical contraindications to continuing
naltrexone are in evidence, treatment will be discontin-
ued. If no contraindications to continuing naltrexone are
in evidence, the next four-week prescription will be sent
to the pharmacy for participant pick-up. Vials will be re-
fitted with a MEMS monitoring system by the pharma-
cist. At week eight, the study physician will complete a
visit identical to week four (i.e., it will include the same
questionnaires, pill counts, blood draw, and medical
visit). However, study participation will terminate follow-
ing the week-eight visit. Participants will be provided
with a discharge recommendation from the study phys-
ician and a referral for continuing treatment if requested
by the participant. At the end of the eight-week visit, the
study coordinator will conduct an exit interview to elicit
qualitative information on the usability and acceptability
of AGATE/SASED.
Power and sample size considerations
The primary outcome will be percent of scheduled doses
taken during the eight-week trial as measured by MEMS.
We will dichotomize participants according to whether
they achieved the adherence criterion of 80%.
Examining antiretroviral medication adherence, Simoni
et al. [29] compared an electronic pager adherence sup-
port intervention, also developed by Talaria, with a peer
adherence support intervention and usual care (i.e., no ad-
herence support). In that study, both interventions lasted
three months; however, pages gradually tapered in the
third month. Participants were characterized as either
100% adherent in the preceding week or not based on
self-report and MEMS. At week two, self-reports indicated
that 100% adherence was achieved by 80.4% in the pager
arm, 63.2% in the peer-support arm, and 64.9% in the
usual-care arm. This represents a medium effect size for
the pager intervention compared with peer intervention
(w=0.36) and usual care (w=0.32). At month three, after
pages had been tapered, self-reports indicated that 100%
adherence was achieved by 57.1% in the pager arm, 56.1%
in the peer-support arm, and 47.4% in the usual-care arm.
This represents no effect for the pager intervention com-
pared with the peer intervention (w=0.02), and a small-
to-medium effect size for the pager intervention com-
pared with usual care (w=0.19). It is important to note
that the pagers used in the Simoni et al. study functioned
only as a high-technology reminder system. The pager did
not assess and reinforce adherence as AGATE will. More-
over, the pages tapered without regard to adherence per-
formance. Therefore, we anticipate a medium effect size
for AGATE compared with SASED (w=0.30) over the
two-month course of the evaluation. Power analysis will
be conducted using G*Power 3 software [30,31]. For a χ2
test with α error probability set to 0.05, a sample size of 88
will yield power of 0.80 to detect effect size w=0.30. Allow-
ing for up to 15–20% attrition between randomization and
discharge, our target number of randomized participants is
105.
Data analysis plan
Preliminary analyses will identify data input errors, out-
liers, and other threats to the integrity of subsequent
analyses. Screening and baseline variables will be exam-
ined to determine whether randomization effectively
produced equivalent groups. Any variable that is not
equivalent between groups at screening or baseline will
be used as a covariable in subsequent analyses as appro-
priate. To test our primary hypothesis that those in the
AGATE condition will be more likely to be adherent
over the course of the study, we will dichotomize the ad-
herence outcomes based on MEMS assessments. Those
who have taken ≥ 80% of scheduled doses will be classi-
fied as adherent; all others will be classified as nonadher-
ent. The χ2 goodness-of-fit test will be conducted. To
test our secondary hypothesis, that those in the AGATE
condition will take significantly more scheduled doses,
we will conduct multivariable analysis of variance with
repeated measures. The dependent variables will be the
AGATE, pill counts, MEMS, and TLFB measures of ad-
herence. To test our tertiary hypothesis, that those in
the AGATE condition will have better drinking out-
comes, we will conduct multivariable analysis of variance
with repeated measures. Percentage of days abstinent,
percentage of heavy drinking days, drinks per drinking
day, and latency to first heavy drinking day will be com-
puted from the TLFB and from AGATE/SASED daily
drinking reports and serve as dependent variables for
this analysis. We will also examine concordance among
AGATE, pill count, MEMS, and TLFB measures of adher-
ence, globally and over time, using bivariable Spearman
rank-order correlations (ρ). Degree of concordance will be
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tested with the κ statistic, which is corrected for chance
association, and we will test for differences in adherence
rates among the adherence measures using nonparametric
Friedman two-way analysis of variance.
Rationale for non-inclusion of a placebo condition
The present study has three primary purposes: to evalu-
ate the effectiveness of AGATE as an adherence-
enhancement intervention, to evaluate the validity and
reliability of AGATE as an adherence-measurement sys-
tem, and to evaluate the feasibility and acceptability of
AGATE in the context of a trial of naltrexone treatment
for problem drinking. The effectiveness of naltrexone
relative to placebo is already established in the literature
[32–34]. Because nonadherence to naltrexone is also
well-documented in the literature [6,14,17,18,21,35–37]
and adherence to naltrexone appears worse than adher-
ence to placebo, presumably due to side effects [38], we
felt that evaluating AGATE as an adherence-enhancement
intervention in an open-label trial without placebo was
sufficient for this efficacy study. Specifically, we are inter-
ested in knowing whether AGATE can help overcome rea-
sons for nonadherence that go hand-in-hand with receipt
of an active drug versus with placebo (e.g., certain mild
drug-induced side effects) as well as reasons for nonadher-
ence that would be expected in both placebo and active
drug conditions (e.g., uncertainty regarding medication ef-
fectiveness, lack of understanding of the need for consist-
ent dosing, waning motivation to reduce drinking,
perceived stigma, reluctance to mix medications with al-
cohol or drugs [38]). Therefore, we wanted to maximize
the number of participants receiving the active drug.
Rationale for the selected control condition (SASED)
An obvious choice of a possible control condition could
have consisted of adding a medication management
(MM) component as was done in the Combining Medi-
cations and Behavioral Interventions for Alcoholism
(COMBINE) study [12,37]. However, due to the add-
itional time spent attending to compliance issues in an
MM component, this method would create differential
clinician attention between conditions. Furthermore, if
participants in one condition received a smart phone
with voice and internet service while the others did not,
one could argue that a differential demand characteristic
would be created between conditions. Because differen-
tial clinician attention and demand characteristics can
create confounds, we reasoned that the most well-
controlled and rigorous test of AGATE would be to cre-
ate a control condition in which participants also receive
a smart phone.
Researchers have previously used electronic diaries
successfully to measure drinking on a daily basis [39] or
episodically in an ecological momentary assessment
paradigm [40]. For example, Bernhardt et al. [39] com-
pared daily self-reports of alcohol consumption collected
using a handheld computer with those collected using
the TLFB method [26] among college students. Both
methods enabled computation of overall alcohol con-
sumption, drinks per drinking day, and number of heavy
drinking days. No significant differences between the
two methods were found. Thus, we felt that a good use
of smart phones in the control condition would be to as-
sess alcohol consumption on a daily basis. We also felt
another good use of smart phones in the control condi-
tion would be to assess side effects on a weekly basis.
Therefore, the control condition for the proposed
study is a smart-phone alcohol and side-effects diary
(SASED).
Discussion
Results from prior randomized trials indicate that optimal
adherence to naltrexone is critical to achieving medication-
related reductions in drinking [7,16–18]. In light of these
findings, the fact that naltrexone shows only modest effi-
cacy across studies [28] could be partly reflective of sub-
optimal procedures for assuring good adherence in many
clinical trials [7]. Thus, implementing behavioral interven-
tions that improve adherence could increase medication ef-
fect sizes in clinical trials as well as improve treatment
outcomes in real-world settings [7]. Promising behavioral
interventions for increasing medication adherence in
people with problem drinking have been developed and
implemented successfully in clinical trials (22). Nonetheless,
the fact that these interventions require ongoing assess-
ment and intervention from clinicians is likely to limit up-
take in naturalistic settings. Conversely, the AGATE
intervention can be delivered on an ongoing basis at min-
imal cost. Moreover, because medication-taking is a behav-
ior that must be enacted daily, adherence interventions
should ideally be capable of reaching the individual on a
frequent basis. Mobile health interventions are well suited
to this objective.
Results from the current trial will inform further de-
velopment of the AGATE system, which is currently
being generalized to apply to any medication type or
regimen. If results of this trial indicate the AGATE sys-
tem is effective for improving medication adherence
among treatment-seeking individuals with alcohol de-
pendence or at-risk drinking, future studies will evaluate
whether it can be effective in other contexts, including
other naturalistic settings. Additionally, user feedback
collected during this trial will be used to tailor subse-
quent iterations of the technology. A future goal is to
make AGATE fully customizable for various medication
schedules and to enable broad use for clinicians and
researchers.
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